Mutagenic damage to mammalian cells by therapeutic alkylating agents

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 355, Issue 1-2, 1996, Pages 41-57

  Sanderson, Barbara J S ^a   Shield, Alison J ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

alkylating agent; DNA damage; mutation; synergism; therapeutic

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CHLOROZOTOCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; ESTRAMUSTINE PHOSPHATE; ESTRAMUSTINE PHOSPHATE SODIUM; IFOSFAMIDE; LOMUSTINE; MELPHALAN; MITOMYCIN; MITOMYCIN C; NITROSOUREA DERIVATIVE; SEMUSTINE; STREPTOZOCIN; THIOTEPA; TRETAMINE;

ANIMAL CELL; DNA DAMAGE; GENOTOXICITY; HUMAN; MUTAGENICITY; MUTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALIA; BACTERIA (MICROORGANISMS); BRASSICACEAE; MAMMALIA;

EID: 0030591653     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/0027-5107(96)00021-8     Document Type: Article

References (117)

1. Aaron, C.S., R. Sorg and D. Zimmer (1989) The mouse bone marrow micronucleus test: evaluation of 21 drug candidates. Mutation Res., 223, 129-40.
2. Ammenheuser, M.M., J.B. Ward Jr, E.B. Whorton, J.M. Kilian and M.S. Legator (1988) Elevated frequencies of 6-thioguanine resistant lymphocytes in multiple sclerosis patients treated with cyclophosphamide: a prospective study. Mutation Res., 204, 509-520.
3. Anderson, D., A. Dhawan, and T.-W. Yu (1995) investigation of bone marrow and germ cells in vivo using the Comet assay. Environ. Mol. Mutagen., 25 (Suppl. 25), 2.
4. Andrews, P.W. and R.R. Tice (1995) A human lymphocyte assay for detecting genotoxic agents using the alkaline single cell gel (SCG) assay. Environ. Mol. Mutagen., 25 (Suppl. 25), 3.
5. Ashby, J. and H. Tinwell (1993) Clastogenicity of chlorambucil to the mouse bone marrow: consideration in relation to its genetic specificity of action in some assays. Mutagenesis, 8, 373-375.
6. Auerbach, C. and J.M. Robson (1946) Action of mustard gas on the bone marrow. Nature, 158, 787-879.
7. Badewitz-Dodd, L.H., K.R. Tuckwell, W.R. Pearce and R. McDougall (Eds.) (1994) MIMS Annual. Australian Edition, 18th Edn., MediMedia Australia Pty Ltd.
8. Baer, J.C., A.A. Freeman, E.S. Newlands, A.J. Watson, J.A. Rafferty and G.P. Margison, (1993) Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br. J. Cancer, 67, 1299-1302.
9. Bean, C.L. and S.M. Galloway (1993) Evaluation of the need for a late harvest time in the assay for chromosome aberrations in Chinese hamster ovary cells. Mutation Res., 292, 3-16.
10. Benedict, W.F., M.S. Baker, L. Haroun, E. Choi and B.N. Ames (1977) Mutagenicity of cancer chemotherapeutic agents in the Salmonella/Microsome Test. Cancer Res., 37, 2209-2213.
11. Benigni, R., F. Palombo, and E. Dogliotti (1992) Multivariate statistical analysis of mutation spectra of alkylating agents. Mutation Res., 267, 77-88.
12. Bertino, J.R. (1992) Antineoplastic drugs, in: Melmon, K.L., H.F. Morrelli, B.B. Hoffman and D.W. Niernenberg (Eds.). Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics, 3rd Edn., New York, McGraw-Hill, pp. 600-641
13. Biesele, J.J., F.S. Philips, J.B. Thiersch, J.H. Burchenal, S.M. Bucktey and C.C. Stock (1950) Chromosome alteration and tumor inhibition by nitrogen mustards: the hypothesis of cross-linking alkylation. Nature, 4235, 1112-1113
14. Black, D.J. and R.B. Livingston (1990a) Antineoplastic drugs in 1990. A review (Part I). Drugs, 39(4), 489-501.
15. Black, D.J. and R.B. Livingston (1990b) Antineoplastic drugs in 1990. A review (Part II). Drugs, 39(5), 652-673.
16. Bogen, K.T. (1995) Improved prediction of carcinogenic potential from mutagenic potencies for chemicals positive from mutagenic potencies for chemicals positive in rodents and the Ames Test. Environ. Mol. Mutagen., 25, 37-49.
17. Bronstein, S.M., J.E. Cochrane, T.R. Craft, J.A. Swenberg and T.R. Skopek (1991) Toxicity, mutagenicity and mutation spectra of N-ethyl-N-nitrosourea in human cell lines with different DNA repair phenotypes. Cancer Res., 51, 5188-5197.
18. Brooks, T.M., S.W. Dean and D.J. Kirkland (1995) The detection of gene mutations in transgenic mice (Muta™Mouse) following administration of known mutagens. Environ. Mol. Mutagen., 25 (Suppl. 25), 6.
19. Burkhart, J.G., B.A. Burkhart, K.S. Sampson and H.V. Malling (1993) ENU-induced mutatgenesis at a single A:T base pair in transgenic mice containing phi X174, Mutation Res., 292, 69-81.
20. Burns, P.A., A.J.E. Gordon and B.W. Glickman (1988) Mutational specificity of N-methyl-N-nitrosourea in the lacI gene of Eschericia coli. Carcinogenesis, 9, 1607-1610.
21. Capucci, M.S., M.E. Hoffmann, M.Z. Zdzienicka and A.T. Natarajan (1995) Streptozocin-induced chromosomal aberrations. SCEs and mutations in CHO-9 parental cells and EM-C11 mutant cell line. Mutation Res., 326, 227-234.
22. Carter, J.L., D.A. Hafler, D.M. Dawson, J. Orav, and H.L. Weiner (1988) Immunosuppression with high-dose IV cyclopnosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology, 38 (Suppl.), 9-14.
23. Chang, T.K.H., G.F. Weber, C.L. Crespi and D.J. Waxman (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res., 53, 5629-5637.
24. Chrysostomou, A, A.A. Morley and R. Seshadri (1984) Mutation frequency in nurses and pharmacists working with cytotoxic drugs. Aust. NZ J. Med., 14, 831-834.
25. Connors, T.A. (1975) Mechanism of action of 2-chloroethylamine derivatives, sulfur mustards, epoxides and aziridines. in: Sartorelli, A.C. and D.G. Johns (Eds.), Handbook of Experimental Pharmacology. Antineoplastic and Immunosuppressive Agents. Vol. XXXVIII/2. Springer-Verlag, Berlin, pp. 18-34.
26. Connors, T.A. (1986) Antitumour alkylating agents: cytotoxic action and organ toxicity. IARC Scientific Publications, 78, 143-145.
27. Crespi, C.L., R. Langenbach, K. Rudo, Y.-T. Chen and R.L. Davies (1989) Transfection of a human cytochrome P450 gene into the human lymphoblastoid cell line, AHH-1, and use of the recombinant cell line in gene mutation assays Carcinogenesis, 10, 295-301.
28. Curtis, R.E., J.D. Boice, W.C. Moloney, L.G. Ries and J.T. Flannery (1990) Leukemia following chemotherapy for breast cancer. Cancer Res., 50, 2741-2746.
29. Davies, M.J., B.J. Phillips and P.C. Rumbsy (1993b) Molecular analysis of mutation at the tk locus of L5178Y mouse-lymphoma cells induced by ethyl methanesulphonate and mitomycin C. Mutation Res., 290, 145-153.
30. Davies, M.J., B.J. Phillips, D. Anderson and P.C. Rumbsy (1993a) Molecular analysis of mutation at the hprt locus of Chinese hamster V79 cells induced by ethyl methanesulphonate and mitomycin C. Mutation Res., 291, 117-124.
31. de Serres, F.J., H.V. Malling and T.-M. Ong (1995) Comparison of the mutagenicity and mutagen specificity of ethylenimine with triethylenemelamine in the ad-3 region of heterokaryon 12 of Neurospora crassa. Mutation Res., 328, 193-205.
32. DeMarini, D.M., H.E. Brockman, F.J. de Serres, H.H. Evans, L.F. Stankowski Jr and A.W. Hsie (1989) Specific-locus mutations induced in eukaryotes (especially mammalian cells) by radiation and chemicals: a perspective. Mutation Res., 220, 11-29.
33. Dempsey, J.L., R. Seshadri and A.A. Morley (1985) Increased mutation frequency following treatment with cancer chemotherapy. Cancer Res., 45, 2873-2877.
34. Durand, M. and D.E.G. Shuker (1994) Preparation of compound-specific and group-specific antibodies to 7-methylguanine and related 7-alkylguanines and their use in immunoaffinity purification. Carcinogenesis, 15(5), 957-961.
35. Eder, J.P., R.C. Bast, W.P. Peters, W.D. Henner, E. Sanchez, S. Schryber, E. Frei III and L.E. Schnipper (1986) Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy. Cancer Res., 46, 4496-4499.
36. Elhajouji, A. and M. Kirsch-Volders (1995) Estimation of threshold doses for aneugens by FISH on sorted micronuclei (MN). Environ. Mol. Mutagen., 25 (Suppl. 25), 14.
37. 6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp. Hematol., 23, 112-116.
38. Falck, K., P. Grohn, M. Sorsa, H. Vainio, E. Heinonen and L.R. Holsti (1979) Mutagenicity in urine of nurses handling cytostatic drugs. Lancet, June 9, 1250-1251.
39. Fenech, M. and S. Neville (1992) Conversion of excision-repairable lesions to micronuclei within one cell cycle in human lymphocytes. Environ. Mol. Mutagen., 19, 27-36.
40. Fiorio, R., R. Vellosi and G. Bronzetti (1994) Effects of spermine on formation of HGPRT mutants induced by ethylmethanesulfonate, methylmethanesulfonate, and mitomycin C in V79 Chinese hamster ovary cells. Environ. Mol. Mutagen., 23, 294-298.
41. Forsti, A. and K. Hemminiki (1986) Unique properties of cisplatin in reactions with nucleophiles. IARC Scientific Publications, 78, 101-110.
42. Friedberg, E.C. (1985) DNA Repair. Freeman, New York.
43. Gerard, B., S. Aamdal, S.M. Lee, S. Leyvraz, C. Lucas, M. D'Incalci, J.P. Bizzari (1993) Activity and unexpected lung toxicity of the sequential administration of two alkylating agents-dacarbazine and fotemustine-in patients with melanoma. Eur. J. Cancer, 29A, 711-719.
44. Gibson, J.F., D. Gompertz and R.B. Hedworth-Whitty (1984) Mutagenicity of urine from nurses handling cytotoxic drugs. Lancet, Jan 14, 100-101.
45. Gibson, D.P., J.A. O'Kelley, M.J. Aardema and N.J. Gorelick (1995) Comparison of assessment of micronuclei and mutations in Lac1 transgenic mice. Environ. Mol. Mutagen., 25 (Suppl. 25), 18.
46. Gilman, A.G., T.W. Rail, A.S. Nies and P. Taylor (Eds.) (1991) Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th Edn., Pergomon Press.
47. Grunwald, H.W. and F. Rosner (1979) Acute leukemia and immunosuppressive drug use. Arch. Intern. Med., 139, 461-466.
48. Hales, B.F. (1983) Relative mutagenicity and teratogenicity of cyclophosphamide and two of its structural analogs. Biochem. Pharmacol., 32, 3791-3795.
49. Hanawalt, P.C. (1991) Heterogeneity of DNA repair at the gene level. Mutation Res., 247, 203-211.
50. Harbach, P.R., A.L. Filipunas, Y. Wang and C.S. Aaron (1992) DNA sequence analysis of spontaneous and N-ethyl-N-nitrosourea-induced hprt mutations arising in vivo in cynomolgus monkey T-lymphocytes. Environ. Mol. Mutagen., 20, 96-105.
51. Hartmann, A., K. Herkommer, M. Glück and G. Speit (1995) DNA-damaging effect of cyclophosphamide on human blood cells in vivo and in vitro studied with the single-cell gel test (Comet assay). Environ. Mol. Mutagen., 25, 180-187.
52. Hemminki, K. (1993) DNA adducts, mutations and cancer. Carcinogenesis, 14, 2007-2012.
53. Hemminki, K. and S. Kallama, (1986) Reactions of nitrogen mustards with DNA. IARC Scientific Publications, 78, 55-70.
54. Henner, W.D., B.J.S. Sanderson, K.J. Johnson and K.K. Walker (1991) Deletion endpoints induced by mechlorethamine in human hprt locus are clustered near exon 6. Proc. Am. Assoc. Cancer Res., 32, 104.
55. Huttner, E., U. Merger, R. Braun and J. Schoneich (1990) Increased frequency of 6-thioguanine-resistant lymphocytes in peripheral blood of workers employed in cyclophosphamide production. Mutation Res., 243, 101-107.
56. IARC (1981) IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, Vol. 26, Some Antineoplastic and Immunosuppressive Agents, IARC, Lyon, France, pp 79-247.
57. Ioannidou, E., T. Lialiaris, D. Mourelatos and J. Dozi-Vassiliades (1989) Synergistic induction of cytogenetic damage by alkylating neoplasties and 5-azacytidine in human lymphocytes. Environ. Mol. Mutagen., 14, 6-12.
58. Jansen, J.G., A.J.L. de Groot, C.M.M. van Teijlingen, P.H.M. Lohman, G.R. Mohn, H. Vrieling, and A.A. van Zeeland (1994) Formation and persistence of DNA adducts in pouch skin fibroblasts and liver tissue of rats exposed in vivo to the monofunctional alkylating agents N-methyl-N-nitrosourea or N-ethyl-N-nitrosourea. Mutation Res., 307, 95-105.
59. Jensen, J.C. and W.G. Thilly (1986) Spontaneous and induced chromosomal aberrations and gene mutations in human lymphoblasts: mitomycin C, methylnitrosourea. and ethylnitrosourea. Mutation Res., 160, 95-102.
60. Kaldor, J.M., N.B. Day, F. Pettersson, E.A. Clarke, D. Pedersen, W, Mehnert, J. Bell, H. Host, P. Prior, S. Karajalainen, F. Neal, M. Koch, P. Band, W. Choi, V.P. Kirn, A. Arslan, B. Zaren, A.R. Belch, H. Storm, B. Kittelmann, P. Fraser and M. Stovall (1990) Leukemia following chemotherapy for ovarian cancer. New Engl. J. Med., 322, 1-6.
61. Kamiguchi, Y., H. Tateno, Y. Iizawa and K. Mikamo (1995) Chromosome analysis of human spermatozoa exposed to antineoplastic agents. Mutation Res., 236, 185-192.
62. Klein, C.B. and T.G. Rossman (1990) Transgenic Chinese hamster V79 cell lines which exhibit variable levels of gpt mutagenesis. Environ. Mol. Mutagen., 16, 1-12.
63. + V79 cell lines differ in their mutagenic response to clastogens. Mutation Res., 304, 217-228.
64. Kolar, G.F. (1986) Carcinogenicity of cytostatic triazenes. IARC Scientific Publications, 78, 111-126.
65. Krepinsky, A., D.W. Bryant, L. Davison, B. Young, J. Heddle, D.R. McCalla, G. Douglas and K. Michalko (1990) Comparison of three assays for genetic effects of antineoplastic drugs on cancer patients and their nurses. Environ, Mol. Mutagen., 15, 83-92.
66. Krishna, G., G. Urda, F. Moore and J. Theiss (1995b) Rat primary spleen-cell culture system for micronuclei and chromosome aberration analyses in vitro. Environ. Mol. Mutagen., 25 (Suppl, 25), 28.
67. Krishna, G., J. Petrere, J. Anderson and J. Theiss (1995a) Cyclophosphamide-induced dominant lethal mutations and micronuclei in mice. Environ. Mol. Mutagen., 25 (Suppl. 25), 28.
68. Kwanyuen, P., J.D. Wilson, J. Williamson, J.A. Campbell, N.F. Cariello and J.S. Allen (1995) Micronucleus induction in bone marrow polychromatic erythrocytes of Han Wistar rats by cyclophosphamide, 5-flourouracil and ethyl methanesulfonate. Environ. Mol. Mutagen., 25 (Suppl. 25), 29.
69. Langlois, R.G., B.A. Nisbet, W.L. Bigbee, D.N. Ridinger and R.H. Jensen (1990) An improved flow cytometric assay for somatic mutations at the glycophorin A locus in humans. Cytometry, 11, 513-521.
70. Lee, C.S. and N.W. Gibson (1991) DNA damage and differential cytotoxicity produced in human carcinoma cells by CC-1065 analogues, U-73,975 and U-77,779. Cancer Res., 51, 6586-91.
71. Lee, C.S. and N.W. Gibson (1993) Nucleotide preferences for DNA interstrand cross-linking induced by the cyclopropylpyrroloindole analogue U-77,779. Biochemistry, 32, 2592-600.
72. Lee, S.M., G.P. Margison, N. Thatcher, P.J. O'Connor and D.P. Cooper (1994a) Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy. Br. J. Cancer, 69, 853-857.
73. Lee, C.S., G.P. Pfeifer and N.W. Gibson (1994b) Mapping of DNA alkylation sites induced by adozelesin and bizelesin in human cells by ligation-mediated polymerase chain reaction. Biochemistry, 33, 6024-30.
74. Li, L.H., T.F. DeKoning, R.C. Kelly, W.C. Krueger, J.P. McGovren, G.E. Padbury, G.L. Petzold, T.L. Wallace, R.J. Ouding, M.D. Prairie, and I. Gebhard (1992) Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res., 52, 4904-13.
75. Liber, H.L., D.W. Yandell and J.B. Little (1989) A comparison of mutation induction at the tk and hprt loci in human lymphoblastoid cells; quantitative differences are due to an additional class of mutations at the autosomal tk locus. Mutation Res., 216, 9-17.
76. Loo, T.L. (1975) Triazenoimidazole derivatives, in: Sartorelli, A.C. and D.G. Johns (Eds.), Handbook of Experimental Pharmacology. Antineoplastic and Immunosuppressive Agents. Vol. XXXVIII/2. Springer-Verlag, Berlin, pp. 544-553.
77. Ludlum, D.B. (1975) Molecular biology of alkylation: an overview, in: Sartorelli, A.C. and D.G. Johns (Eds.), Handbook of Experimental Pharmacology. Antineoplastic and Immunosuppressive Agents. Vol. XXXVIII/2. Springer-Verlag, Berlin, pp. 6-17.
78. Mattison, J.D., W. Roake, N. Powles, S.L. Beck and B. Burlinson (1995) Comets, hedgehogs and apoptotic cells. Environ. Mol. Mutagen., 25 (Suppl. 25), 34.
79. McCarron, M.A., A. Kutlaca and A.A. Morley (1989) The HLA-A mutation assay: Improved technique and normal results. Mutation Res., 225, 189-193.
80. Mitchell, R.B., M.E. Dolan, L. Janisch, N.J. Vogelzang, M.J. Ratain and R.L. Schilsky (1994) Sequential therapy with dacarbazine and carmustine: a phase I study. Cancer Chemother. Pharmacol., 34, 509-514.
81. Morley, A.A, K.J. Trainor, J.L. Dempsey and R.S. Seshadri (1985) Methods for study of mutations and mutagenesis in human lymphocytes. Mutation Res., 147, 363-367.
82. Morrison, R.T. and R.N. Boyd (1987) Organic Chemistry, 5th Edn., Allyn & Bacon, Boston, pp. 182-194
83. Moscow, J.A. and K.H. Cowan (1988) Multidrug resistance. J. Natl. Cancer Inst., 80, 14-20.
84. Mudipalli, A., S.S. Nanadur, A.E. Maccubbin and H.L. Gurtoo (1995) Mutations induced by dacarbazine activated with cytochrome P-450. Mutation Res., 327, 113-120.
85. 6-benzylguanine and ethacrynic acid in haematological malignancies. Anticancer Res., 13, 2155-2159.
86. Murti, J.R., K.J. Schimenti, and J.C. Schimenti (1994) A recombination-based transgenic mouse system for genotoxicity testing. Mutation Res., 307, 583-595.
87. Myhr, B.C. (1991) Validation studies with Muta™Mouse: A transgenic mouse model for detecting mutations in vivo. Environ. Mol. Mutagen., 18, 308-315.
88. Palmer, R.G., C.A. Smith-Burchnell, C.J. Dore and A.M. Denman (1986) Thioguanine-resistanl mutations induced by cytotoxic drugs in lymphocytes of patients with connective tissue diseases. Br. J. Rheumatol., 25, 376-379.
89. Palmer, R.G., C.A. Smith-Burchnell, B.K. Pelton, W. Hylton and A.M. Denman (1988) Use of T cell cloning to detect in vivo mutations induced by T cell cloning to detect in vivo mutations induced by cyclophosphamide, Arthritis Rheumat., 31, 757-761.
90. Penman, B.W., C.L. Crespi, E.A. Komives, H.L. Liber and W.G. Thilly (1983) Mutation of human lymphoblast exposed to low concentrations of chemical mutagens for long periods of time. Mutation Res., 108, 417-436.
91. Peters, W.P., W.D. Henner, L.B. Grochow, G. Olsen, S. Edwards, H. Stanbuck, A. Stuart, J. Gockerman, J. Moore, R.C. Bast, H.F. Seigler and O.M. Colvin (1987) Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res., 47, 6402-6406.
92. Philip, P.A., J. Carmichael, K. Tonkin, T.A. Ganesan and A.L. Harris (1994) A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. Eur. J. Cancer., 30A, 1027-1029.
93. Povirk, L.F. and D.E. Shuker (1994) DNA damage and mutagenesis induced by nitrogen mustards. Mutation Res., 318, 205-226.
94. Reichardt, J.K.V. and P. Berg (1988) Conservation of short patches of amino acid sequence amongst proteins with a common function but evolutionary distinct origin: implications for cloning genes and for structure-function analysis. Nucleic Acid Res., 16, 9017-9026.
95. Ribrag, V., L. Massaad, F. Janot, M. Bissery, O. Parise Jr., A. Gouyette and G.C. Chabot (1994) Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo. Leukemia Res., 18, 829-835.
96. Richardson, K.K., F.C. Richardson, R.M. Crosby, J.A. Swenberg and T.R. Skopek (1987) DNA base changes and alkylation following in vivo exposure of Eschencia coli to N-methyl-N-nitrosourea or N-ethyl-N-nitrosourea. Proc. Natl. Acad. Sci. USA, 84, 344-348.
97. Rosenkranz, H.S. and G. Klopman (1995) Relationship between electronegativity and genotoxicity. Mutation Res., 328, 215-227.
98. Russell, L.B. (1991) Factors that affect the molecular nature of germ-line mutations recovered in the mouse specific-locus test. Environ. Mol. Mutagen., 18, 298-302.
99. Saenger, W. (1984) Principles of Nucleic Acid Structure. Springer-Verlag, New York. pp. 178-241
100. Salmon, S.E. and A.C. Sartorelli (1992) Cancer Chemotherapy, in: Katzung, B.G. (Ed.), Basic and Clinical Pharmacology, 5th Edn., Appleton & Lange, Prentice Hall USA, pp. 766-800.
101. Sanderson, B.J.S., K.J. Johnson and W.D. Henner (1991) Dose-dependent cytotoxic and mutagenic effects of antineoplastic alkylating agents on human lymphoblastoid cells. Environ. Mol. Mutagen, 17, 238-243.
102. Seraphim, L.A., S.D. Perrapato, H.K. Slocum, Y.M. Rustum and R.P. Huben (1991) In vitro study of the interaction of doxorubicin, thiotepa and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer. J. Urol., 145, 613-617.
103. Shea, T.C., G. Claflin, K.E. Comstock, B.J.S. Sanderson, N.A. Burstein, E.J. Keenan, B. Mannervik and W.D. Henner (1990) Glutathione transferase activity and isoenzyme composition in primary human breast cancers. Cancer Res., 50, 6848-6853.
104. Shelby, M.D., D.K. Gulati, R.R. Tice and J.P. Wojciechowski (1989) Results of tests for micronuclei and chromosomal aberrations in mouse bone marrow cells with human carcinogens 4-aminobiphenyl, treosulphan, and melphalan. Environ. Mol. Mutagen., 13, 339-342.
105. Singh, N.P., R.R. Tice, R.E. Stephens and E.L. Schneider (1991) A microgel electrophoresis technique for the direct quantitation of DNA damage and repair in individual fibroblasts cultured on microscope slides. Mutation Res., 252, 289-296.
106. 1 mice exposed to N-ethyl-N-nitrosourea. Proc. Natl. Acad. Sci. USA, 89, 7866-7870.
107. Speit, G., W. Menz, C. Röscheisen and B. Köberle (1992) Cytogenetic and molecular characterization of the mutagenicity of chtorambucil in V79 cells. Mutation Res., 283, 75-81.
108. Staiano, N., J.F. Gallelli, R.H. Adamson and S.S. Thorgiersson (1981) Lack of mutagenic activity in urine from hospital pharmacists admixing antitumour drugs. Lancet, March 14, 615-616.
109. Suzuki, T., M. Hayashi, T. Sofuni and B.C. Myhr (1993) The concomitant detection of gene mutation and micronucleus induction by mitomycin C in vivo using lacZ transgenic mice. Mutation Res., 285, 219-224.
110. Thacker, J. (1985) The molecular nature of mutations in cultured mammalian cells: a review. Mutation Res., 150, 431-442.
111. Tice, R.R., G.H.S. Strauss and W.P. Peters (1992) High dose alkylating agents with autologous bone-marrow support in patients with breast cancer: Preliminary assessment on DNA damage in individual peripheral blood lymphocytes using single cell gel electrophoresis technique assay. Mutation Res., 271, 101-113.
112. Tucker, M.A., C.N. Coleman, R.S. Cox, A. Varghese and S.A. Rosenberg (1988) Risk of second cancer after treatment for Hodgkin's disease. New Engl. J. Med., 318, 76-81.
113. Venitt, S., C. Crofton-Sleigh, J. Hunt, V. Speechley and K. Briggs (1984) Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs: Urinary mutation assays and urinary platinum as markers of absorption. Lancet, Jan. 14, 74-77.
114. Vogel, E.W. and M.J.M. Nivard (1994) The subtlety of alkylating agents in reactions with biological macromolecules. Mutation Res., 305, 13-32.
115. Won, C.D., K.H. Lee, M.S. Kong and T.H. Ma (1995) Clastogenicity of cyclophosphamide evaluated with the mouse-spermatid-micronucleus (Mus-Spmn) bioassay. Environ. Mol. Mutagen., 25 (Suppl. 25), 58.
116. Yamada, M., T. Sofuni, and T. Nohmi (1992) Preferential induction of AT-TA transversion, but not deletions, by chlorambucil at the hisG428 site of Salmonella typhimurium TA102. Mutation Res., 283, 29-33.
117. - diploid human fibroblasts. Carcinogenesis, 15, 939-945.